Targeting Genomic Instability: An Achilles Heel in Cancer?
Free and open to the public
Dr. Kevin Mills is a molecular biologist who studies fundamental cancer processes. He received his B.A. in molecular biology from the ¸ßÇå²»¿¨¸£Àû of Colorado, Boulder and completed his Ph.D. in Biology from the Massachusetts Institute of Technology. Dr. Mills completed a 5-year post-doctoral fellowship with Fred Alt at Harvard Medical School/Childrens Hospital in Boston, MA. Dr. Mills has since moved to The Jackson Laboratory where he is now an Associate Professor. He is also a member of the ¸ßÇå²»¿¨¸£Àû of Maine Graduate School and holds a faculty appointment at Tufts ¸ßÇå²»¿¨¸£Àû School of Medicine.
Dr. Mills’ laboratory is examining how nuclear architecture, genome structure and DNA repair mechanisms all influence this process as well as working with a mouse model of human leukemia/lymphoma to better understand the molecular pathobiology of the human disease. They are also investigating the connection between DNA damage and natural variations in aging, using the mouse as a model system to explore how genome stability control changes with age.
In 2012 Dr. Mills co-founded Cyteir Therapeutics, a biotechnology startup endeavoring to develop new cancer therapeutics that target genomic instability pathways.
Lunch will be provided.
Hosted by: John Streicher, Ph.D.
Address
St. Francis Room, Ketchum Library
United States